Abstract:1667 Substitutions and deletions in exons in the tyrosine kinase domain of the EGFR gene (exons 18 to 24) in lung tumors have been associated with sensitivity to molecular target therapeutic agents classified as tyrosine kinase inhibitors (TKIs). Among the TKIs are gefitinib and erlotinib, which produce objective responses in 10-20% of advanced NSCLC patients after chemotherapy. Erlotinib prolongs survival in these patients. The relationship between mutation and response and survival is imperfect, suggesting that other factors may play a role in determining sensitivity to TKIs. Recently we found EGFR amplification to be frequent in NSCLC (13%) and to be related to gefitinib response and survival. In this report, we examined genomic DNAs from 78 NSCLC and 20 SCLC lung cancer cell lines. Exons 18-21 of the tyrosine kinase domain were amplified and sequenced for the presence of mutations. Mutations were found in none of the SCLC lines and 8 of 78 NSCLC lines (10%), namely NCI-H820, NCI-H1650, NCI-H1975, NCI-H3255, HCC827, HCC2279, HCC2935 and HCC4006. These cell lines were initiated from 7 Caucasian patients and one of Oriental origin. Most patients were light or never smokers. Six of the mutations were deletions in exon 19 and two were the L858R point mutation in exon 21. Dual color fluorescence in situ hybridization analysis was performed in 35 NSCLC lines using the EGFR/CEP 7 probe (Vysis/Abbott). EGFR gene amplification was identified in 7 of these lines, all carrying EGFR mutations. H3255, HCC827, HCC2259, and HCC4006 had large, clustered gene amplification in all cells; H1650 had focal gene amplification with large gene clusters in approximately 30% of cells; NCI-H820 and HCC2935 showed small gene clusters in interphase nuclei and apparently normal metaphase chromosomes, supporting the hypothesis that rearranged chromosomes harbor gene duplications. The remaining mutated line, NCI-1975 had no evidence of amplification. Chromosomes harboring large amplicons including EGFR were distinct among the lines. H3255 showed gene clusters in two distinct chromosomes, a large der(7) with three layers of gene clusters and a large metacentric with numerous layers of gene clusters in both arms. HCC827, HCC4006 and H1650 carried the EGFR amplification in the long arm of der(7) with large gene clusters interspaced by centromeric sequences. Preliminary in vitro testing showed that the majority of the mutated lines were sensitive to gefitinib and that there was a correlation between gefitinib sensitivity and the degree of gene amplification. These results identified gene amplification as frequently associated with mutations in the tyrosine kinase domain of the EGFR gene in NSCLC cell lines and support the role of both amplification and mutation in the sensitivity to TKIs.

The Influence of K-Ras Mutation on Epidermal Growth Factor Receptor Inhibitor Sensitive Cell Lines

K-ras Mutation-Induced Resistance to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cells

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

HER2 Overexpression Reverses the Relative Resistance of EGFR-mutant H1975 Cell Line to Gefitinib.

Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib

Recombinant Expression of Different Mutant K-ras Gene in Pancreatic Cancer Bxpc-3 Cells and Its Effects on Chemotherapy Sensitivity

Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity

Mefatinib As First-Line Treatment of EGFR Sensitizing Mutation-Positive Non-Small-cell Lung Cancer: A Phase III Efficacy and Biomarker Study.

Better Survival with Epidermal Growth Factor Receptor Exon 19 Deletion Than with Exon 21 Mutation in Gefitinib-Treated Non-Small Cell Lung Cancer Patients is Due to Differential Inhibition of Downstream Signals

Kras Mutations And Resistance To Egfr-Tkis Treatment In Patients With Non-Small Cell Lung Cancer: A Meta-Analysis Of 22 Studies

Transient Transfection of Short Hairpin RNA Targeting Epidermal Growth Factor Receptor into Lung Adenocarcinoma A549 Cell Line and Its Effect on Cell Growth and Sensitivity to Cytotoxic Drugs

Interferon-α Reduces the Gefitinib Sensitivity of Human Non-Small Cell Lung Cancer

Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation

The Role of Insulin-Like Growth Factor 1 Receptor in Drug Resistance of Non-Small Cell Lung Cancer A549 and H292 Cells

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China

Gefitinib sensitivity in non-small cell lung cancer (NSCLC) cell lines associates with mutation and amplification of the epidermal growth factor receptor (EGFR) gene

The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer.

Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status

The distribution of genetic mutations correlated with resistance to KRASG12C inhibitors in Chinese patients with lung cancer.

Clinical Outcome of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors Therapy for Patients with Overlapping Kirsten Rat Sarcoma 2 Viral Oncogene Homolog and Epidermal Growth Factor Receptor Gene Mutations